Neutrophil support for patients with cancer receiving myelosuppressive chemotherapy
|
|
- Dwain Domenic Snow
- 6 years ago
- Views:
Transcription
1 Appropriate dosing of NEUPOGEN in recovery of neutrophil counts in myelosuppressive regimens Neutrophil support for patients with cancer receiving myelosuppressive chemotherapy Indication NEUPOGEN is indicated to decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. Please see Important Safety Information on page 2 and full Prescribing Information. 1
2 NEUPOGEN Important Safety Information NEUPOGEN stimulates neutrophil production Contraindication NEUPOGEN is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors, such as filgrastim or pegfilgrastim. Splenic Rupture Splenic rupture, including fatal cases, has been reported following the administration of NEUPOGEN. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. Acute Respiratory Distress Syndrome Acute respiratory distress syndrome (ARDS) has been reported in patients receiving NEUPOGEN. Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS. Discontinue NEUPOGEN in patients with ARDS. Serious Allergic Reactions Serious allergic reactions, including anaphylaxis, have been reported in patients receiving NEUPOGEN. The majority of reported events occurred upon initial exposure. Provide symptomatic treatment for allergic reactions. Allergic reactions, including anaphylaxis, in patients receiving NEUPOGEN can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue NEUPOGEN in patients with serious allergic reactions. Sickle Cell Disorders Sickle cell crisis, in some cases fatal, has been reported with the use of NEUPOGEN in patients with sickle cell trait or sickle cell disease. Capillary Leak Syndrome Capillary leak syndrome (CLS) has been reported after G-CSF administration, including NEUPOGEN, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include the need for intensive care. Thrombocytopenia Thrombocytopenia has been reported in patients receiving NEUPOGEN. Monitor platelet counts. Leukocytosis White blood cell counts of 100,000/mm 3 were observed in about 2% of patients with cancer receiving myelosuppressive chemotherapy who received NEUPOGEN at dosages > 5 mcg/kg/day. It is recommended to monitor CBCs at least twice weekly, and adjust NEUPOGEN dosing as clinically indicated to help mitigate risk of leukocytosis. Dosages of NEUPOGEN that increase the absolute neutrophil count (ANC) beyond /mm 3 may not result in any additional clinical benefit. Discontinuation of NEUPOGEN therapy usually resulted in a 50% decrease in circulating neutrophils within 1 to 2 days with a return to pretreatment levels in 1 to 7 days. Cutaneous Vasculitis Cutaneous vasculitis has been reported in patients treated with NEUPOGEN. In most cases the severity of cutaneous vasculitis was moderate or severe. Most of the reports involved patients with severe chronic neutropenia (SCN) receiving long-term NEUPOGEN therapy. Hold NEUPOGEN therapy in patients with cutaneous vasculitis. NEUPOGEN may be started at a reduced dose when the symptoms resolve and the absolute neutrophil count (ANC) has decreased. Potential Effect on Malignant Cells The possibility that NEUPOGEN acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, cannot be excluded. Simultaneous Use with Chemotherapy and Radiation Therapy Not Recommended The safety and efficacy of NEUPOGEN given simultaneously with cytotoxic chemotherapy have not been established. Do not use NEUPOGEN in the period 24 hours before or after the administration of cytotoxic chemotherapy. The safety and efficacy of NEUPOGEN have not been evaluated in patients receiving concurrent radiation therapy. Avoid the simultaneous use of NEUPOGEN with chemotherapy and radiation therapy. Nuclear Imaging Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient, positive bone-imaging changes. This should be considered when interpreting bone-imaging results. The most common adverse reactions ( 5% difference in incidence, compared to placebo) are pyrexia, pain, rash, cough, and dyspnea. Neutrophils are a type of granulocyte, which are important infection-fighting white blood cells produced in the bone marrow 1 Febrile neutropenia, the development of fever and associated infection due to a low number of neutrophils, is a medical emergency that can occur in patients with cancer receiving myelosuppressive chemotherapy 1, NEUPOGEN binds to cell surface receptors on hematopoietic cells in the bone marrow. 3 NEUPOGEN stimulates neutrophil progenitor cell proliferation and differentiation. 3-5 NEUPOGEN requires daily dosing because of its short elimination half-life NEUPOGEN molecules are cleared predominantly via filtration in the kidneys. 7 In addition, NEUPOGEN is cleared by binding to neutrophils already in circulation. 7 NEUPOGEN speeds up neutrophil maturation, leading to an increased number of mature neutrophils released into the circulation. 5,6 The elimination half-life of NEUPOGEN is approximately 3.5 hours. Therefore, NEUPOGEN requires daily dosing. NEUPOGEN should not be administered in the period 24 hours before through 24 hours after the administration of chemotherapy. 3 NEUPOGEN stimulates neutrophil proliferation, which helps reduce the risk of infection in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever. Please see full Prescribing Information. 2 3
3 NEUPOGEN stimulates proliferation and decreases maturation time of neutrophils Effect of NEUPOGEN on neutrophil proliferation and maturation 4,5,8,9 NEUPOGEN decreased the severity and duration of chemotherapy-induced neutropenia The timing and depth of neutrophil nadirs vary based on patient factors and the type of chemotherapy administered 10,11 With endogenous granulocyte colony-stimulating factor (G-CSF) MITOTIC PHASE POSTMITOTIC PHASE Myeloblast Promyelocyte Myelocyte Metamyelocyte Band cell Mature segmented cell A longer duration of severe neutropenia (absolute neutrophil count [ANC] < /L) is directly related to an increased risk of febrile neutropenia 12 Chemotherapy-induced neutrophil nadir was less severe with 10 days of NEUPOGEN support 13 3 to 9 days 5 to 7 days With exogenous G-CSF (NEUPOGEN) Circulating neutrophils Log ANC ( 10 9 /L) in Cycle Grade 4 neutropenia* Chemotherapy administered NEUPOGEN or placebo administered NEUPOGEN Placebo MITOTIC PHASE Myeloblast Promyelocyte Myelocyte POSTMITOTIC PHASE Metamyelocyte Band cell Mature segmented cell Day *Grade 4 neutropenia = ANC < /L. Circulating neutrophils Adapted from Crawford J, et al. N Engl J Med Data from a multicenter, randomized, double-blind, placebo-controlled trial that included 199 patients with small-cell lung cancer receiving up to 6 cycles of chemotherapy with cyclophosphamide, doxorubicin, and etoposide. Patients were randomly assigned to receive either placebo or NEUPOGEN 24 hours postchemotherapy (beginning on day 4 and continuing through day 17 of a 21-day cycle, unless the postnadir neutrophil count after day 12 exceeded /L, in which case growth factor was discontinued for the remainder of the cycle). The primary endpoint was infection as manifested by fever with neutropenia (temperature 38.2 C, with an absolute neutrophil count < 1.0 x 10 9 /L). 13 Select secondary endpoints from Crawford J, et al. 13 Endpoint Placebo NEUPOGEN Decrease P Value 3 to 9 days 1 day Median duration of grade 4 neutropenia in first cycle Median duration of fever with neutropenia in first cycle 6 days 3 days 50% < days 4 days NS IMPORTANT SAFETY INFORMATION 4 Contraindication NEUPOGEN is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors, such as filgrastim or pegfilgrastim. Please see additional Important Safety Information on page 2. 5
4 Less-than-labeled doses of NEUPOGEN were associated with a greater incidence of febrile neutropenia NEUPOGEN used for 7 days decreased the rate of febrile neutropenia by 65% compared with dosing of < 7 days 14 Incidence of Febrile Neutropenia in Patients Receiving Secondary Prophylaxis, % % < 7 Days (Mean = 4.7 Days) Days Receiving NEUPOGEN 65% Reduction Adapted from Scott SD, et al. J Manag Care Pharm Data obtained through review of patient medical records for the Oncology Practice Pattern Study at 12 sites between 1991 and Study included patients (n = 170) with intermediate-grade non-hodgkin s lymphoma treated with first-line CHOP-21 chemotherapy and receiving primary or secondary prophylaxis* with NEUPOGEN. Filgrastim was administered for 7 days in most cycles (Group 2 received 7 days of filgrastim in 579 cycles, and Group 1 received < 7 days of filgrastim in 73 cycles). Seven days was chosen as the cutoff based on the empirical frequency distribution of the days of prophylactic NEUPOGEN treatment. It was also supported by an abstract by Meza et al, in which the lower bound for the mean number of days of NEUPOGEN therapy required for 95% of the population to achieve ANC recovery (mean minus 2 times the standard deviation) was approximately 7 days. 12,14 6% 7 Days (Mean = 10.1 Days) NEUPOGEN reduced febrile neutropenia consistently across 3 studies when dosed appropriately and for the proper duration NEUPOGEN reduced febrile neutropenia in patients receiving myelosuppressive chemotherapy 13,15,16 Incidence of Febrile Neutropenia, % % 47% Reduction NEUPOGEN PI (N = 210) P < % 53% Trillet-Lenoir (N = 130) P < % Reduction 26% 44% Placebo NEUPOGEN Pettengell (N = 80) Adapted from NEUPOGEN PI; Trillet-Lenoir, et al, Eur J Cancer, 1993; Pettengell, et al, Blood, Two randomized, placebo-controlled, double-blind, multicenter phase 3 trials in patients with small-cell lung cancer (SCLC) receiving myelosuppressive chemotherapy and one randomized, open-label, parallel-controlled, single-center trial in patients with NHL receiving myelosuppressive chemotherapy. 3,13,15,16 In SCLC studies, NEUPOGEN was initiated 24 hours after chemotherapy and administered daily until the postnadir ANC was greater than /L or for a maximum of 14 days. 3,13,15 In the NHL study, NEUPOGEN was administered for 13 weeks, except on days preceding and during treatment with doxorubicin, cyclophosphamide, or etoposide, and discontinued at week 13 or when the ANC reached /L, whichever came first. 16 P =.04 48% Reduction 23% *Prophylaxis was defined as NEUPOGEN started within 5 days of chemotherapy administration. 14 Therapeutic dosing of NEUPOGEN helps reduce the incidence of febrile neutropenia. Study Tumor Type Primary Endpoint(s) Selected Secondary Endpoints Crawford et al 13 SCLC Fever with neutropenia Duration and severity of neutropenia; incidence of antibiotic use Trillet-Lenoir et al 15 SCLC Fever with neutropenia Duration and severity of neutropenia; use of antibiotics Pettengell et al 16 NHL Fever with neutropenia; neutropenia; cytoxic dose intensity Duration and severity of neutropenia; incidence of documented infection; use of antibiotics 6 IMPORTANT SAFETY INFORMATION Splenic Rupture Splenic rupture, including fatal cases, has been reported following the administration of NEUPOGEN. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. Please see additional Important Safety Information on page 2. 7
5 Dose NEUPOGEN based on weight, and with proper scheduling and administration, to help reduce the risk of febrile neutropenia Recommended dosage and administration provide neutrophil support for patients with cancer receiving myelosuppressive chemotherapy 3 Starting dosage of 5 mcg/kg/day administered as a single daily injection by subcutaneous injection by short intravenous infusion (15 to 30 minutes) or by continuous intravenous infusion Obtain a CBC and platelet count before instituting therapy and monitor twice weekly during therapy Consider dose escalation in increments of 5 mcg/kg for each chemotherapy cycle according to the duration and severity of ANC nadir Recommend stopping NEUPOGEN if ANC increases > /mm 3 Administer 24 hours after cytotoxic chemotherapy; do not administer within the 24-hour period prior to chemotherapy Administer daily for up to 2 weeks or until the ANC has reached /mm 3 following the expected chemotherapy-induced neutrophil nadir IMPORTANT SAFETY INFORMATION Acute Respiratory Distress Syndrome Acute respiratory distress syndrome (ARDS) has been reported in patients receiving NEUPOGEN. Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS. Discontinue NEUPOGEN in patients with ARDS. Please see additional Important Safety Information on page 2. References 1. National Cancer Institute. Dictionary of Cancer Terms. Available at: Accessed June 1, Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103: NEUPOGEN (filgrastim) prescribing information, Amgen. 4. Jandl JH. Granulocytes. In: Blood: Textbook of Hematology. 2nd ed. Boston, MA: Little Brown & Co; 1996: Dexter TM. Granulocyte colony stimulating factor: from laboratory bench to clinical use. Eur J Cancer. 1994;30A(suppl 3):S15-S Dale DC. Physiology, Function, and Role of the Neutrophil in Host Defense. Thousand Oaks, CA: Amgen, Inc; 1994: Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy. 2007;27: Núñez C, Brady G (Testa NG, Lord BI, Dexter TM, eds). Neutrophils and macrophages. In: Hematopoietic Lineages in Health and Disease. New York, NY: Marcel Dekker; 1997: Kim SK, Demetri GD. Hematol Oncol Clin North Am. 1996;10: McEvoy G. AHFS Drug Information Bethesda, MD: American Society of Health-System Pharmacists; Saab YB, Sharaf L, Zeidan I, Bizri A. Cancer Ther. 2003;1: Meza L, Baselga J, Holmes FA, et al, for the Pegfilgrastim Study Group. Abstract presented at: 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, FL. 13. Crawford J, Ozer H, Stoller R, et al. N Engl J Med. 1991;325: Scott SD, Chrischilles EA, Link BK, et al. J Manag Care Pharm. 2003;9(suppl 2): Trillet-Lenoir V, Green J, Manegold C. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A: Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-hodgkin s lymphoma: a randomized controlled trial. Blood. 1992;80;
6 Help reduce the risk of febrile neutropenia Use NEUPOGEN at the appropriate dose and duration NEUPOGEN helps stimulate neutrophil production NEUPOGEN helps decrease the severity and duration of chemotherapyinduced neutropenia for patients with cancer receiving myelosuppressive chemotherapy Dose NEUPOGEN based on weight and with proper scheduling and administration to help reduce the risk of febrile neutropenia Efficacy has been shown to be compromised when NEUPOGEN was dosed at less than the label-indicated dose The most common adverse reactions ( 5% difference in incidence, compared to placebo) are pyrexia, pain, rash, cough, and dyspnea Please see Important Safety Information on page 2 and full Prescribing Information Amgen. All rights reserved. USA
7 Weight-based dosing NEUPOGEN weight-based dosing Dosing information in patients receiving myelosuppressive chemotherapy 1 NEUPOGEN is available in single-dose vials and syringes Single-Dose Vials SingleJect Single-Dose Syringes Filgrastim Fill Volume Fill Volume 300 mcg 1.0 ml 0.5 ml 480 mcg 1.6 ml 0.8 ml Recommended dosing by patient weight The recommended starting dose of NEUPOGEN is 5 mcg/kg/day. Please see additional dosing and administration information on page 8 of the dosing brochure. Patient Weight Patient Weight NEUPOGEN Starting Dose (5 mcg/kg/day) 60 kg HCPs should draw the appropriate dose of NEUPOGEN from the 300-mcg vial for patients weighing 60 kg < 50 kg < 110 lb < 250 mcg 55 kg 121 lb 275 mcg 60 kg 132 lb 300 mcg > 60 to < 100 kg HCPs should draw the appropriate dose of NEUPOGEN from the 480-mcg vial for patients weighing > 60 kg to < 100 kg 65 kg 143 lb 325 mcg 70 kg 154 lb 350 mcg 75 kg 165 lb 375 mcg 80 kg 176 lb 400 mcg 85 kg 187 lb 425 mcg 90 kg 198 lb 450 mcg 95 kg 209 lb 475 mcg 100 kg HCPs should draw the appropriate dose of NEUPOGEN from two 300-mcg vials for patients weighing 100 kg 100 kg 220 lb 500 mcg 105 kg 231 lb 525 mcg 110 kg 242 lb 550 mcg Indication NEUPOGEN is indicated to decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. Please see Important Safety Information on the next page and full Prescribing Information. 1. NEUPOGEN (filgrastim) prescribing information, Amgen. 1
8 NEUPOGEN Important Safety Information Contraindication NEUPOGEN is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors, such as filgrastim or pegfilgrastim. Splenic Rupture Splenic rupture, including fatal cases, has been reported following the administration of NEUPOGEN. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. Acute Respiratory Distress Syndrome Acute respiratory distress syndrome (ARDS) has been reported in patients receiving NEUPOGEN. Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS. Discontinue NEUPOGEN in patients with ARDS. Serious Allergic Reactions Serious allergic reactions, including anaphylaxis, have been reported in patients receiving NEUPOGEN. The majority of reported events occurred upon initial exposure. Provide symptomatic treatment for allergic reactions. Allergic reactions, including anaphylaxis, in patients receiving NEUPOGEN can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue NEUPOGEN in patients with serious allergic reactions. Sickle Cell Disorders Sickle cell crisis, in some cases fatal, has been reported with the use of NEUPOGEN in patients with sickle cell trait or sickle cell disease. Capillary Leak Syndrome Capillary leak syndrome (CLS) has been reported after G-CSF administration, including NEUPOGEN, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include the need for intensive care. Thrombocytopenia Thrombocytopenia has been reported in patients receiving NEUPOGEN. Monitor platelet counts. Leukocytosis White blood cell counts of 100,000/mm 3 were observed in about 2% of patients with cancer receiving myelosuppressive chemotherapy who received NEUPOGEN at dosages > 5 mcg/kg/day. It is recommended to monitor CBCs at least twice weekly, and adjust NEUPOGEN dosing as clinically indicated to help mitigate risk of leukocytosis. Dosages of NEUPOGEN that increase the absolute neutrophil count (ANC) beyond /mm 3 may not result in any additional clinical benefit. Discontinuation of NEUPOGEN therapy usually resulted in a 50% decrease in circulating neutrophils within 1 to 2 days with a return to pretreatment levels in 1 to 7 days. Cutaneous Vasculitis Cutaneous vasculitis has been reported in patients treated with NEUPOGEN. In most cases the severity of cutaneous vasculitis was moderate or severe. Most of the reports involved patients with severe chronic neutropenia (SCN) receiving long-term NEUPOGEN therapy. Hold NEUPOGEN therapy in patients with cutaneous vasculitis. NEUPOGEN may be started at a reduced dose when the symptoms resolve and the absolute neutrophil count (ANC) has decreased. Potential Effect on Malignant Cells The possibility that NEUPOGEN acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, cannot be excluded. Simultaneous Use with Chemotherapy and Radiation Therapy Not Recommended The safety and efficacy of NEUPOGEN given simultaneously with cytotoxic chemotherapy have not been established. Do not use NEUPOGEN in the period 24 hours before or after the administration of cytotoxic chemotherapy. The safety and efficacy of NEUPOGEN have not been evaluated in patients receiving concurrent radiation therapy. Avoid the simultaneous use of NEUPOGEN with chemotherapy and radiation therapy. Nuclear Imaging Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient, positive bone-imaging changes. This should be considered when interpreting bone-imaging results. The most common adverse reactions ( 5% difference in incidence, compared to placebo) are pyrexia, pain, rash, cough, and dyspnea. Please see full Prescribing Information Amgen. All rights reserved. USA
FREQUENTLY ASKED QUESTIONS
ZARXIO FORMULARY INFORMATION FREQUENTLY ASKED QUESTIONS INDICATIONS: Patients with Cancer Receiving Myelosuppressive Chemotherapy ZARXIO is indicated to decrease the incidence of infection as manifested
More informationUNIT PRICING INFORMATION 1
ZARXIO FORMULARY INFORMATION UNIT PRICING INFORMATION 1 TYPE OF INJECTABLE NATIONAL DRUG CODE (NDC) NUMBER UNIT QUANTITY UNIT PRICE (WAC) Single-dose preservative-free, prefilled syringes with an UltraSafe
More informationGuidelines on Use of Haematopoietic Growth Factors in Adult Oncology and Haemato-oncology Patients
Guidelines on Use of Haematopoietic Growth Factors in Adult Oncology and Haemato-oncology Patients The recombinant human granulocyte-colony stimulating factor (GCSF) of choice is Biosimilar filgrastim
More informationPRODUCT MONOGRAPH. (filgrastim) Sterile Solution for Injection. (Subcutaneous or Intravenous Use Only) Hematopoietic Agent
PRODUCT MONOGRAPH Pr Neupogen (filgrastim) Sterile Solution for Injection (Subcutaneous or Intravenous Use Only) 300 g/ml and 600 g/ml Hematopoietic Agent Granulocyte Colony Stimulating Factor Amgen Canada
More informationLEARN. about. Please see Important Safety Information on pages 3-5 and enclosed full Prescribing Information.
LEARN about on pages 3-5 and enclosed 2 3? What is ZARXIO (filgrastim-sndz)? ZARXIO is a man-made form of granulocyte colony-stimulating factor (G-CSF) called filgrastim. G-CSF is a substance produced
More informationColony Stimulating Factors: Neupogen (filgrastim) Document Number: MODA-0235
Colony Stimulating Factors: Neupogen (filgrastim) Document Number: MODA-0235 Last Review Date: 11/21/2017 Date of Origin: 10/17/2008 Dates Reviewed: 6/2009, 12/2009, 06/2010, 7/2010, 09/2010, 12/2010,
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 16 June 2005 EMEA/CHMP/94526/2005 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) ANNEX GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
More informationA GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE
A GUIDE TO THIS REFLECTIONS B327-02 RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for
More informationPROPRIETARY NAME REVIEW(S)
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125553Orig1s000 PROPRIETARY NAME REVIEW(S) PROPRIETARY NAME REVIEW Division of Medication Error Prevention and Analysis (DMEPA) Office of Medication
More informationPHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec)
PHYSICIAN OFFICE BILLING INFORMATION SHEET FOR IMLYGIC (talimogene laherparepvec) INDICATION IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable
More informationUse of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey
VOLUME 8 NUMBER 3 September 2017 JOURNAL OF CLINICAL AND EXPERIMENTAL INVESTIGATIONS ORIGINAL ARTICLE Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research
More informationPlatelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD
Platelet Refractoriness: The Basics Martin H. Bluth, MD, PhD Complete Toxicology Laboratories, LLC Objectives Define platelet refractoriness and associated conditions that may cause platelet refractoriness.
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationPatient Case and Question
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida
More informationInvestigator Guide Reporting of Unanticipated Problems to the IRB
Committee for Protection of Human Subjects The IRB for New York Medical College, Westchester Medical Center, Metropolitan Hospital Center (HHC), and Westchester Institute for Human Development, Terence
More informationAnti- THrombosis with Enoxaparin in intubated Adolescents
Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question
More informationDenosumab for the prevention of skeletal related events in patients with multiple myeloma first line
NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationMyeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation
Myeloma Bone Disease Current and Future Treatment A Publication of The Bone and Cancer Foundation What Is Multiple Myeloma? Multiple Myeloma is a cancer that results from a malignant change in a particular
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationThis talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse
This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is
More informationPhysician Orders - Adult
Physician Orders - Adult attach patient label here Title: Direct Thrombin Inhibitor (DTI) Protocol Orders Height: cm Weight: kg Allergies: [ ] No known allergies [ ]Medication allergy(s): [ ] Latex allergy
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationScottish Medicines Consortium
Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the
More informationHeparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.
Heparin Induced Eric Kraut, MD Professor of Internal Medicine The Ohio State University Medical Center Heparin Induced Heparin induced thrombocytopenia occurs in up to 5 % of patients receiving unfractionated
More informationFactor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate
Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary
More informationDr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationLong-Term Follow-Up in Gene Transfer Clinical Research
Long-Term Follow-Up in Gene Transfer Clinical Research Jan P. Vleck, MD CIP Institutional Biosafety Committee Services A Division of WIRB www.ibcservicepoint.com ibcs@wirb.com What is LTFU? the collection
More informationuniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B -- Second-dose Cohort Demonstrates Dose Response with All Patients
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationSYNAGIS (palivizumab) injection, for intramuscular use Initial U.S. Approval: 1998
US-10672 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS (palivizumab)
More informationThere are currently 4 US Food and Drug
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationOff-Label Use of FDA-Approved Drugs and Biologicals
Off-Label Use of FDA-Approved Drugs and Biologicals Last Review Date: January 12, 2018 Number: MG.MM.AD.06cC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician
More informationTexas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request
Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous
More informationPassive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016
Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
23 July 2015 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationThree Methods for Phase I/II Clinical Trials, with Application to Allogeneic
Three Methods for Phase I/II Clinical Trials, with Application to Allogeneic Stem Cell Transplantation Peter F. Thall, PhD Biostatistics Department M.D. Anderson Cancer Center Workshop on Clinical Trial
More informationRoche s Hemlibra significantly reduced bleeds in phase III study in haemophilia A
Media Release Basel, 20 November 2017 Roche s Hemlibra significantly reduced bleeds in phase III study in haemophilia A HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison
More informationThe science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION REMICADE
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REMICADE safely and effectively. See full prescribing information for REMICADE. REMICADE (infliximab)
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationElevated Immunoglobulins and Paraproteins
Elevated Immunoglobulins and Paraproteins NWL Pathology GP Study Afternoon Thursday 19 th October 2017 Dr Aristeidis Chaidos Consultant Haematologist and Honorary Senior Clinical Lecturer Hammersmith Hospital,
More informationClinical Policy: Eculizumab (Soliris) Reference Number: ERX.SPMN.225
Clinical Policy: (Soliris) Reference Number: ERX.SPMN.225 Effective Date: 01/17 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationManaging Risk and Uncertainty Through the Drug Life cycle. Recent FDA Initiatives. Theresa Mullin, PhD
Managing Risk and Uncertainty Through the Drug Life cycle Recent FDA Initiatives Theresa Mullin, PhD Director Office of Strategic Programs US FDA Center for Drug Evaluation and Research October 14, 2014
More informationTransfusion effect of random donor platelet and single donor platelet in thrombocytopenic patients at tertiary care hospital of South Gujarat
International Journal of Research in Medical Sciences Unagar CA et al. Int J Res Med Sci. 2017 Jul;5(7):3033-3037 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20172983
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationCorporate Medical Policy Genetic Testing for Fanconi Anemia
Corporate Medical Policy Genetic Testing for Fanconi Anemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_fanconi_anemia 03/2015 3/2017 3/2018 12/2017 Description
More informationBETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular
BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular Medicine Cardiovascular Division Brigham and Women s Hospital
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationImmunotherapy in myeloma
Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to
More informationSERIOUS ADVERSE EVENTS
EVENTS Introduction Timely reporting of Serious Adverse Events (SAEs) is required by regulations of the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). Such reporting is not
More informationBiomarkers: Physiological & Laboratory Markers of Drug Effect
Biomarkers: Physiological & Laboratory Markers of Drug Effect Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration January 23, 2014 1 Why Are Biomarkers Important?
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512 Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Monique
More informationThe clinical utility of IPF in thrombocytopenia
The clinical utility of IPF in thrombocytopenia Platelets platelets Platelets are the smallest blood cells which are released by cytoplasmic blebbing of megakaryocytes with an average size of 2um. Normal
More informationUnderstanding clinical research trials
Understanding clinical research trials Dr. Isabelle Fleury Medical Hemato-oncologist Hôpital Maisonneuve-Rosemont CIUSSS de l Est-de-l Île-de-Montréal Goals of this presentation Better understand clinical
More informationAVONEX (Interferon beta-1a) IM Injection DESCRIPTION
AVONEX (Interferon beta-1a) IM Injection DESCRIPTION AVONEX (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.44 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationBiotest AG. Jefferies Healthcare Conference New York, June 7-10, 2016
. Jefferies Healthcare Conference New York, June 7-10, 2016 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial
More informationClinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404
Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this
More informationCost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany
International Journal of Clinical Pharmacology and Therapeutics, Vol. No. /2012 (1-9) Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany Original 2012
More informationComparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017
Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical
More informationClinical Policy: Octreotide Acetate (Sandostatin Injection, Sandostatin LAR Depot) Reference Number: CP.PHAR.40
Clinical Policy: (Sandostatin Injection, Sandostatin LAR Depot) Reference Number: CP.PHAR.40 Effective Date: 03/10 Last Review Date: 03/17 See Important Reminder at the end of this policy for important
More informationDoctor of Pharmacy Course Descriptions
Doctor of Pharmacy Course Descriptions Required Courses Pharmacy Practicum II (7002) Second practicum with direct instruction by an experienced preceptor to increase the student's awareness of the pharmacist's
More informationInvestor Update. Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Investor Update Basel, 1 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III
More informationAutomated Hematology System. Your Complete Choice
XE-5000 Automated Hematology System Your Complete Choice Advanced Technology Solutions to Meet Your Lab s Needs Even with these challenges, the need for hematology testing has remained steady or continued
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationDRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes
NHS ONEL & Barking, Havering & Redbridge University Hospitals Trust Shared Care Guidelines DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED
More informationFunction, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking
Function, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking Joy Gould BB(ASCP)C, SBB, CQIA(ASQ), CPHQ Thomas Jefferson University Hospital Philadelphia, PA Objectives Define Multiple
More informationCORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016
CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016 Positive remimazolam data in pivotal U.S. Phase III study for procedural sedation during colonoscopy
More informationInsight to Gene Techno Science Co.,Ltd
Unlimited drug discovery from the beginning Ticker symbol: 4584 Insight to Gene Techno Science Co.,Ltd November 2017 2 Corporate Overview Chief Executive Founded March 2001 Masaharu Tani, President Listed
More informationGenomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)
Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Strategies for modern biomarker and drug - Oct 3, 2014 Sequencing the cancer genome
More informationMedia Release. Roche s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors. Basel, 09 December 2017
Media Release Basel, 09 December 2017 Roche s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors Newly approved Hemlibra demonstrated superior efficacy compared
More informationEbola Facts. October 14, 2014
Ebola Facts October 14, 2014 Symptoms of Ebola Initial symptoms are nonspecific - may include fever, chills, myalgias, and malaise. Patients can progress to develop gastrointestinal symptoms: severe watery
More informationClotting Disorder Therapy
Last Review Date: October 13, 2017 Number: MG.MM.PH.25b Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationPharmacy. Medication. Checks
Pharmacy Medication Checks Module 2 Table of Contents Section A... 1 A.1 Clinical Medication Order Check... 1 A.2 Final Product and Computer Order Entry Check... 1 Section B... 2 B.1 Documentation of Pharmacy
More informationRegulatory hurdles and opportunities
Regulatory hurdles and opportunities Professor Roger Finch Nottingham University Hospitals & University of Nottingham, UK Drug licensing and regulation Mandatory for market authorisation Supports the public
More informationTREATMENT OVERVIEW themmrf.org
MULTIPLE MYELOMA TREATMENT OVERVIEW themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters Kathy Giusti
More informationThe Drug Development Process and Design of Clinical Trials
The Drug Development Process and Design of Clinical Trials Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 Clinical Trial Design Guidance Clinical Trial:
More informationGSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma
GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma 12 December 2017 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking
More informationEffects of Antibiotic Treatment on the Results of Nested ACCEPTED. Polymerase Chain Reactions for Scrub Typhus
JCM Accepts, published online ahead of print on 0 August 00 J. Clin. Microbiol. doi:0./jcm.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationOutline. References. Marshall,1
Outline Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University College of Pharmacy J-marshall@csu.edu
More informationGoldman Sachs Health Care Conference
Goldman Sachs Health Care Conference Laguna Niguel, California June 14, 2006 George Morrow Executive Vice President Global Commercial Operations Safe Harbor Statement This presentation contains forward-looking
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More informationMEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication
MEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication Guide each time you get more ribavirin tablets. There may
More informationWhen to Stop Dose Escalation: MTD, MLD or?
When to Stop Dose Escalation: MTD, MLD or? Henri CAPLAIN First Joint Annual Meeting, AGAH Club Phase 1 STRASBOURG, France 1 So called MTD STOP FIM No MTD? 2 WHY WE NEED TO REACH THE MAXIMUM TOLERATED DOSE
More informationMultiple Sclerosis Agents Drug Class Prior Authorization Protocol
Multiple Sclerosis Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has been developed through review
More informationBrincidofovir (CMX001) is Well Tolerated in Highly Immunocompromised Pediatric Patients
Brincidofovir (CMX001) is Well Tolerated in Highly Immunocompromised Pediatric Patients V.K. Prasad 1, M. Grimley 2, G. Papanicolaou 3, L. Yu 4, D. Florescu 5, T. Brundage 6, H. Momméja-Marin 6, J. Kurtzberg
More informationMicrosphere Brachytherapy Sources and Devices
Microsphere Brachytherapy Sources and Devices REVISED AUGUST 2008 Questions should be directed to: Ashley Tull (240) 888-7129 or Ronald Zelac (301) 415-7635 or MedicalQuestions.Resource@nrc.gov Licensing
More informationContent on this page requires a newer version of Adobe Flash Player.
Content on this page requires a newer version of Adobe Flash Player. 13-1-2018 IV vesicants and pain while a vesicant will cause tissue damage if it escapes. Ciprofloxacin is not designated as a vesicant
More informationClinical Trial Risk in Non-Hodgkin s Lymphoma: Endpoint and Target Selection
Clinical Trial Risk in Non-Hodgkin s Lymphoma: Endpoint and Target Selection Jayson L. Parker 1, Zoe Yi Zhang 1, Rena Buckstein 2 1. Biology Department, Master of Biotechnology Program, University of Toronto,
More information